1.原文连结(必须检附)：
http://ppt.cc/T68W
2.原文内容：
Second-Line nal-IRI (MM-398) Shows Consistent Improvement in Clinical
Outcomes in Metastatic Pancreatic Cancer
JAN 16, 2015
A deeper dive of data from NAPOLI-1, a randomized, controlled, open-label
phase III trial conducted in patients with gemcitabine-refractory metastatic
pancreatic cancer, bolsters support for use of MM-398 plus 5-fluorouracil
(5-FU)/leucovorin over 5-FU/leucovorin in the second-line setting (Abstract
234). Patients who received at least 80% of planned treatment during the
first 6 weeks of the study achieved a 3.8-month improvement in survival when
MM-398 was added to the chemotherapy backbone, according to data presented by
Li-Tzong Chen, MD, PhD, of the National Institute of Cancer Research and the
National Health Research Institutes in Taiwan.
3.心得/评论(必需填写)：
原文未完 请连接网址

意思好像是MM-398跟5-Fu 结合治疗，确实有显治疗效但是临床试验显示仍有少数呕吐症状…跪求医学系翻译第一次看到fell out of favor 有点傻眼，后来仔细研究一下，才知道MM-398的药证受FDA快速审查的细节是跟5-Fu(服药癌注射剂)搭配使用的前提下受审的5-Fu好像本身在化疗使用上就有副作用，所以毒性问题应该不是文章的重点，重点在于该药对胰脏癌的新型疗法吧。星期一市场乐观解读，那应该就是涨停了。推楼上，这癌真的很恶。最近一位朋友也得这种癌，希希望能有效治疗，让得了这类疾病的人都能得到治疗生技类股需要领头羊

利多吧 至于到底是生是死要等药证开牌 有得涨了